How Does Spravato Work in the Brain? The Science of Esketamine, Simplified

How Spravato works in the brain matters more than you might think. The mechanism is the reason it works in hours instead of weeks, the reason it can succeed when SSRIs have failed, and the reason it can be added to your current antidepressant rather than replacing it. Here's the plain-English version of the science — no neuroscience degree required. 

Why SSRIs target serotonin (and where they hit a limit) 

The serotonin theory of depression dominated psychiatry for thirty years. SSRIs (selective serotonin reuptake inhibitors) increase serotonin availability between brain cells. For many patients, that's enough. For a substantial minority, it isn't — and the reason is that depression involves more than serotonin. The brain is more complicated than any single chemical. 

What Spravato targets instead 

Spravato (esketamine) works on the glutamate system, specifically the NMDA receptor. Glutamate is the brain's main excitatory neurotransmitter — it shapes how neurons communicate, learn, and form new connections. In depression, this system shows specific dysfunction: weaker connections, less plasticity, less of the protein BDNF that supports new neural growth. 

The synaptic plasticity story 

Within hours of a Spravato dose, the brain produces a surge of BDNF and starts building new synaptic connections. This is what neuroscientists mean when they talk about "neuroplasticity" — and it's the leading explanation for why Spravato works so fast. You're not just relieving symptoms. The brain is actively rewiring some of the circuits that depression had weakened. 

Why it works in hours, not weeks 

SSRIs slowly raise serotonin and slowly produce changes downstream. Spravato directly triggers the plasticity cascade that those downstream changes were trying to reach. Many patients feel a shift within 24 hours of a session, and most who respond reach a clear response by the end of the four-week induction phase. 

What this means for relapse and maintenance 

Because Spravato strengthens specific neural circuits, the changes don't disappear the moment you stop dosing. After induction, most patients move to weekly or biweekly maintenance, with the goal of gradually extending the interval as the brain consolidates the gains. Eventually many patients can taper. 

Who tends to respond best 

The strongest predictors of response are clearer than most psychiatric medications. Patients with classic depressive symptoms — low mood, anhedonia, sleep disturbance — tend to respond well. Patients with primarily psychotic features or active substance use generally need different approaches first. 

CTA 

Ask about a science-first patient education session — we walk you through what's happening in your brain in 20 minutes.